Free Trial

Titan Medical (TMDIF) Competitors

Titan Medical logo
$0.45 +0.01 (+2.27%)
(As of 12/17/2024 ET)

TMDIF vs. DCTH, ANGO, RCEL, NPCE, CERS, CVRX, OSUR, CATX, ANIK, and LUNG

Should you be buying Titan Medical stock or one of its competitors? The main competitors of Titan Medical include Delcath Systems (DCTH), AngioDynamics (ANGO), AVITA Medical (RCEL), NeuroPace (NPCE), Cerus (CERS), CVRx (CVRX), OraSure Technologies (OSUR), Perspective Therapeutics (CATX), Anika Therapeutics (ANIK), and Pulmonx (LUNG). These companies are all part of the "surgical & medical instruments" industry.

Titan Medical vs.

Titan Medical (NASDAQ:TMDIF) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.

In the previous week, Titan Medical's average media sentiment score of 0.00 beat Delcath Systems' score of -1.00 indicating that Titan Medical is being referred to more favorably in the media.

Company Overall Sentiment
Titan Medical Neutral
Delcath Systems Negative

Delcath Systems has a consensus target price of $21.50, suggesting a potential upside of 96.17%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Titan Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Delcath Systems
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Titan Medical has a net margin of 0.00% compared to Delcath Systems' net margin of -150.70%. Titan Medical's return on equity of -82.31% beat Delcath Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Titan MedicalN/A -82.31% -51.47%
Delcath Systems -150.70%-338.16%-104.02%

Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 17.9% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Titan Medical has higher earnings, but lower revenue than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Medical$17.63M2.91$6.95M$0.059.00
Delcath Systems$22.64M15.48-$47.68M-$1.35-8.12

Delcath Systems received 30 more outperform votes than Titan Medical when rated by MarketBeat users.

CompanyUnderperformOutperform
Titan MedicalN/AN/A
Delcath SystemsOutperform Votes
30
25.64%
Underperform Votes
87
74.36%

Summary

Titan Medical and Delcath Systems tied by winning 8 of the 16 factors compared between the two stocks.

Get Titan Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMDIF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMDIF vs. The Competition

MetricTitan MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$3.73M$4.29B$5.03B$8.97B
Dividend YieldN/A41.44%4.81%4.06%
P/E Ratio-0.3624.72133.1816.92
Price / Sales2.9143.621,119.91116.20
Price / Cash0.0244.2040.6337.94
Price / Book0.437.054.754.71
Net Income$6.95M$13.83M$118.34M$225.20M
7 Day Performance0.60%-5.65%11.78%-2.58%
1 Month Performance-35.71%-0.73%9.77%3.57%
1 Year PerformanceN/A40.87%29.99%16.54%

Titan Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMDIF
Titan Medical
N/A$0.45
+2.3%
N/A+599.8%$3.73M$17.63M-0.364Gap Down
DCTH
Delcath Systems
2.407 of 5 stars
$11.58
-2.4%
$21.50
+85.7%
+216.8%$370.21M$2.07M-8.7976
ANGO
AngioDynamics
4.3519 of 5 stars
$8.73
+24.7%
$12.00
+37.5%
+19.2%$354.70M$303.91M-1.35748High Trading Volume
RCEL
AVITA Medical
2.0488 of 5 stars
$13.52
+3.4%
$16.50
+22.0%
-6.5%$354.49M$50.14M0.00130News Coverage
Positive News
NPCE
NeuroPace
3.7764 of 5 stars
$11.39
+1.0%
$14.60
+28.2%
+14.7%$339.99M$65.42M0.00170Analyst Forecast
News Coverage
CERS
Cerus
3.0234 of 5 stars
$1.80
+0.8%
$3.63
+101.9%
-24.4%$333.35M$156.37M0.00625
CVRX
CVRx
3.9169 of 5 stars
$13.69
+1.6%
$16.67
+21.7%
-50.6%$332.12M$39.29M-5.16200Analyst Revision
Positive News
OSUR
OraSure Technologies
4.3707 of 5 stars
$4.04
+3.3%
$6.67
+65.0%
-50.7%$301.36M$224.26M27.00638Positive News
CATX
Perspective Therapeutics
3.4389 of 5 stars
$3.87
+2.9%
$15.14
+291.3%
N/A$261.57M$1.43M0.00116Positive News
ANIK
Anika Therapeutics
4.1298 of 5 stars
$17.50
+0.3%
$24.50
+40.0%
-28.4%$256.38M$166.66M0.00357Positive News
LUNG
Pulmonx
2.8556 of 5 stars
$6.43
+0.5%
$14.67
+128.1%
-50.6%$253.92M$68.68M-4.36250Positive News

Related Companies and Tools


This page (NASDAQ:TMDIF) was last updated on 12/19/2024 by MarketBeat.com Staff
From Our Partners